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Abstract 
 
 
Cardiac imaging is under intense scrutiny as a contributor to health care costs, with multiple initiatives 
under way to reduce and eliminate inappropriate testing. Appropriate use criteria are valuable guides to 
selecting imaging studies, but until recently have focused on the test rather than the patient. Patient-
centered means are needed in order to define the true value of imaging for patients in specific clinical 
situations. This article provides a definition of high value cardiac imaging.  A paradigm to judge the 
efficacy of echocardiography in the absence of randomized controlled trials is presented. Candidate 
clinical scenarios are proposed in which echocardiography constitutes high value imaging, as well as 
stratagems to increase the likelihood that high value cardiac imaging takes place in those circumstances. 
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Cardiac imaging has come under intense scrutiny as a contributor to rising health care costs in the 
United States.  Attention has been focused on the number of cardiac imaging studies performed, 
including echocardiography. Volume is easy to measure; a far more difficult – and more important – task 
is to ascertain the value of imaging for specific patients or groups of patients. The critical issue is not 
how many studies are being done, but that they are done in circumstances where the results will 
enhance the care of the patient – and not done when the results will not make a difference – so that 
studies lead to better outcomes. 
Increased demand for testing is due to both patient- and physician-related factors (1, 2). Among the 
drivers are physician training which encourages a culture of completeness regardless of cost or of effect 
on others; misaligned financial incentives; effective marketing of new technologies to physicians in the 
absence of comparative effectiveness data with which physicians can assess the value of that 
technology; and fear of malpractice suits, encouraging the practice of defensive medicine. On the 
patient side, Americans are enamored of high technology and may perceive that more tests are by 
definition equal to better care. Direct-to-consumer marketing influences patients’ preferences for 
testing; and a health care system in which patients are insulated from the true fiscal costs of testing also 
drives demand. 
Recent data indicate that the rate at which cardiac imaging is performed not only is no longer increasing 
but has begun to drop. While the General Accounting Office (GAO) reported in 2008 that Medicare 
spending on imaging services under the Part B physician fee schedule more than doubled from 2000 
through 2006, a subsequent MEDPAC Report to Congress noted that annual rate of growth in the 
number of echocardiograms provided per Medicare beneficiary was only 2.6% between 2005 and 2009, 
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and decreased by 0.8% per annum between 2009 and 2010. (3) On the cost side, payments to 
cardiologists for noninvasive diagnostic imaging decreased a total of 33% between 2006 and 2010, 
reversing the increases seen during the preceding six years. (4) Multiple explanations have been cited 
for this phenomenon, which is sometimes referred to as “bending the cost curve.”  They include the 
promulgation of appropriate use criteria for cardiac imaging by professional societies such as the 
American College of Cardiology Foundation (ACCF) and the American Society of Echocardiography (ASE), 
among others. These documents evaluate the relative benefits and risks of an imaging study to 
determine whether it is reasonable to consider performing the study for a specific indication. (5) The 
terminology used to describe the three appropriateness categories has evolved for greater clarity since 
their original publication. Studies for a specific indication were initially divided into Appropriate, 
Uncertain or Inappropriate categories. The terminology has been revised to Appropriate Care, May be 
Appropriate Care, and Rarely Appropriate Care, recognizing that a study which is rarely appropriate may 
be precisely correct for a specific patient. (6) Stated another way, the goal for Rarely Appropriate studies 
is not zero! Education programs such as the American Board of Internal Medicine’s “Choosing Wisely” 
campaign have been directed at patient and providers. Commercial insurers have turned to radiology 
benefits managers (RBM’s) in an attempt to reduce test ordering which they deem inappropriate, while 
Medicare has adopted payment reductions to providers. 
Reducing Overutilization 
The interest in limiting inappropriate cardiac testing stems not just from containing costs. Excess testing 
carries the potential for downstream ill effects. When a study which may have good specificity is 
ordered on a population in whom a disorder has a low prevalence, the few “abnormal” results are more 
likely to be false positives than true positives. This can cause anxiety on the part of the patient and leads 
to unwarranted further testing which carries its own inherent risks. Conversely, a false negative result 
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provides false reassurance and the potential for delayed diagnosis. These concepts are explicitly 
recognized by the ACCF in its definition of an appropriate imaging study as “one in which the expected 
incremental information, combined with clinical judgment, exceeds the expected negative 
consequences by a sufficiently wide margin for a specific indication that the procedure is generally 
considered acceptable care and a reasonable approach for the indication.” (5) 
Appropriate use stratagems have been employed to examine and vet imaging studies once they have 
been ordered, to determine whether they are being ordered for appropriate reasons. Methodologies 
focusing on studies after they have been ordered are suited to reducing overutilization. Research in 
community as well as academic settings has shown that from 9-20% of transthoracic and stress 
echocardiograms are ordered for inappropriate indications. (7-11) A much smaller proportion of 
requested transesophageal studies is rated as inappropriate. (12) The reasons for the disparity have not 
been studied, but might include differences in specialties of the ordering physicians (i.e., cardiologists 
versus non-cardiologists) for transesophageal studies compared with transthoracic or stress 
echocardiography. The ease with which a transthoracic or stress echocardiogram can be ordered, 
contrasted with the fact that transesophageal studies are semi-invasive and are directly performed by a 
cardiologist who must actively assent to their performance, may play a role in differing rates of 
appropriateness.  Applying appropriate use criteria had previously been a manual undertaking, 
consisting of matching the clinical scenario to a list of criteria on paper and uncovering the 
appropriateness score. An application for myocardial perfusion imaging is available for both major 
smartphone platforms, and one for echocardiography has been announced. The American College of 
Cardiology has designed Imaging in FOCUS, a voluntary, web-based decision support program designed 
to reduce inappropriateness in cardiac imaging. FOCUS demonstrated a reduction in inappropriate 
SPECT myocardial perfusion imaging ordering among participants, from 11% of studies before using 
FOCUS to 5% after. (13)  ASE has co-developed a FOCUS module for transthoracic echocardiography. It is 
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reasonable to expect comparable improvements in the degree of study appropriateness when this tool 
is applied to transthoracic echocardiography, but this hypothesis has yet to be tested beyond a pilot 
study. (11). FOCUS is evolving into a robust, multi-modality program which links with commercially 
available electronic health records and provides integrated decision support at the point of order entry. 
(14)  
Defining and identifying high value imaging 
In the quest for high value imaging, rooting out cardiac imaging studies which are of questionable 
appropriateness by looking at the study is one part of the solution.  However, if examining 
appropriateness begins once a test has been ordered, the process is entered at the midpoint of the 
dimensions of care framework for evaluating the quality of cardiac imaging described by the ACCF 
(Figure 1).  This framework starts with the patient, recognizing that efforts at enhancing the value of 
imaging studies must be patient-centric rather than test-centric. Focusing efforts at the patient level 
uncovers not only which patients do not need an imaging study, but also identifies patients who should 
have imaging studies to detect or risk stratify diseases.  Such high value imaging may lead to 
management changes which improve outcomes; or alternatively, lead to the imaging study which most 
conclusively and efficiently excludes a disease, thereby reducing both patient anxiety and downstream 
costs. This approach might better be conceptualized as “bending the value curve,” since the goal of 
managing cardiac imaging is not just lower costs, but higher value to the patient and the health system.  
The concept of developing an outcomes-based imaging cycle backed by evidence is not new (15) but 
bears explication, particularly as the American health care system continues to transform. 
Value in health care has been defined as health outcomes achieved per dollar spent. (16)  Determining 
what is high value cardiac imaging requires measurable outcomes which are specific to a given 
condition. Outcomes, in the numerator, must be achieved efficiently; that is, the total cost of care for 
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the condition must be calculated, and not merely the cost of an individual service.  A more expensive 
test which reduces the overall cost of care may be a good investment of health care dollars. Diagnostic 
studies do not by themselves cure, or change outcomes.  Yet, high value imaging, by being performed in 
the correct part of the care cycle, conceptually can reduce the overall cost of care if it leads to a better 
health outcome.  While the most critical outcomes for patients are increased survival, and recovery or 
improved health, other metrics include time to recovery, avoiding treatment-related side effects, 
avoidance of complications, sustained health and function, and avoiding care-induced illnesses. 
The highest level of evidence for the value of an imaging study would come from a randomized, 
controlled trial which measures specified outcomes. An example of such a study is the PROspective 
Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) Trial, a randomized trial funded by 
the National Heart, Lung and Blood Institute of the clinical effectiveness of diagnostic strategies in 
patients with chest pain, who are randomized to either functional (exercise ECG, stress 
echocardiography or stress nuclear) testing versus anatomic testing (coronary CT angiography). (17) 
Randomized trials for an accepted technology which is already in clinical use – such as echocardiography 
– as part of a diagnostic and treatment strategy are unlikely to be conducted, due to the large number 
of conditions for which echocardiography is performed, and perhaps also due to lack of sponsor 
enthusiasm for investing in what are perceived to be mature technologies. 
An alternate, frequently cited paradigm to judge the value of imaging employs a six-tiered, hierarchical 
model to conceptualize diagnostic imaging as part of a larger system whose goal is to treat patients 
effectively and efficiently. Level 1 is technical efficacy, comprising variables needed to produce a high 
quality image. Level 2 is diagnostic accuracy efficacy, such as percent of correct diagnoses, positive and 
negative predictive value, sensitivity and specificity, as well as receiver operating curves. Level 3, 
diagnostic thinking efficacy, describes the percentage of cases in which the image was helpful in making 
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the diagnosis, the difference in the clinician’s estimation of post- versus pre-test probability and the like. 
Level 4, therapeutic efficacy, consists of the percentage of times the image affects management or 
changes the diagnostic or therapeutic plan. Level 5 describes patient outcome efficacy, being the 
percentage of patients who improve after the test compared with those without it, morbidities avoided, 
change in quality-adjusted life years (QALYs) based on the test, and similar metrics. Finally, level 6, 
societal efficacy, comprises the benefits and costs of the imaging strategy from a societal viewpoint. (18) 
(Table 1) 
The value of cardiac imaging can be assessed if information about the higher levels of efficacy cited in 
the model is available. For a given condition, an imaging study can lead to changes in diagnostic thinking, 
such as uncovering the presence and severity of a disorder. Conversely, a test may confirm the absence 
of a condition, such a decline in left ventricular systolic function during a course of cancer 
chemotherapy, allowing treatment to continue as planned by the treating clinician. The test results bring 
about an evidence-based change in management that has been proven in randomized, controlled trials 
to improve patient outcomes. This approach might constitute an adequate surrogate for randomized, 
controlled trials of the imaging modality itself (19, 20)   
Aspects of the candidate imaging study itself also enter into the value equation. In all forms of testing, a 
good candidate predictor should have a favorable risk-benefit ratio, reasonable cost, acceptability and 
convenience, all of which are characteristic of echocardiography. (21) With respect to candidate 
conditions, a “commonsense checklist” would consist of the following.  One should apply the predictor 
to diseases with major morbidity, for which some effective treatment is available which is not equally 
effective for all persons. The candidate test should allow more accurate classification of individuals into 
categories in which treatment is or is not indicated. The incremental prediction should be beyond what 
can be achieved with information which is already available. There should be consensus about and 
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standardization of established predictors, and the predictor should be unambiguously defined and 
measured. (21) 
Opportunities to achieve high value cardiac imaging 
Examples of cardiac conditions with significant morbidity which fit these criteria abound. In each case, 
echocardiography reclassifies persons non-invasively, painlessly and without the use of ionizing 
radiation, based on standardized criteria such as those for chamber quantification, stress 
echocardiography and valvular regurgitation which have been promulgated in a series of guidelines 
published by ASE and ACCF. (22-24) 
An example candidate condition is heart failure (HF), which affects an estimated 5.7 million people in 
the United States. (25)  Many Class I recommended therapies for heart failure with reduced left 
ventricular ejection fraction are supported by Level of Evidence A; that is, they are recommended based 
on multiple randomized, controlled trials or meta-analyses conducted in multiple populations. Therapies 
including angiotensin converting enzyme inhibitors or angiotensin receptor blockers; beta blockers; 
implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death; 
and cardiac resynchronization have been shown to reduce symptoms, decrease hospitalizations and 
increase survival, depending on stage and symptom class. Treatment of systolic heart failure is 
predicated upon identifying the clinical predictor decreased systolic left ventricular function, usually via 
two-dimensional echocardiography, which is described as “[t]he single most useful diagnostic test in the 
evaluation of patients with HF.” (26) 
Chronic mitral regurgitation serves as another example. This disorder is characterized by a long latent 
period in which patients can remain asymptomatic even in the face of developing left ventricular 
dilation and systolic dysfunction; yet even patients with preserved left ventricular ejection fraction may 
be at increased risk of death. Mitral valve surgery performed in an asymptomatic individual whose 
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ejection fraction has fallen below 60% is likely to prevent further deterioration in left ventricular 
function and improve longevity, although the level of evidence is less robust (Level B: limited 
populations evaluated; data derived from a single randomized trial or nonrandomized studies).  Once 
the ejection fraction falls even lower, the risk of surgery increases and postoperative survival is less. 
Thus there exists a golden moment for patients with chronic severe mitral regurgitation, wherein 
identification of the severity of regurgitation and tracking left ventricular systolic function leads to 
surgical therapy which improves outcomes, and conversely where outcomes are appreciably worse if 
the golden moment is missed. (27) 
Other conditions where opportunities exist to achieve high value cardiac imaging leading to effective, 
evidence-based treatments are listed in Table 2. (26, 28-31) 
Enhancing the likelihood that high value cardiac imaging is provided 
The risk of missed opportunities might increase as health care in the United States reorganizes into 
episodes of care for a specific patient, for a specified condition, over a defined period of time. Global 
payment schemes in which providers assume financial risk can be perceived as carrying with them 
financial incentives to underutilize services, including imaging. (32) It is thus incumbent on the 
cardiology profession to define what constitutes high value cardiac imaging in each care bundle or 
episode of care. Even under a fee-for-service system where there are no incentives to underutilize 
services, underuse of necessary care is common. (33) Nearly 40% of Medicare beneficiaries with newly 
diagnosed heart failure do not have an assessment of left ventricular function, a recommended 
performance measure for these patients. (34) Recent studies applying the appropriate use criteria to 
cardiac testing reveal evidence of missed opportunities to detect and correctly treat heart disease. A 
retrospective study of appropriate use criteria for coronary revascularization of patients with stable 
coronary artery disease revealed that only 69% of patients with an appropriate indication for 
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revascularization actually underwent revascularization. (35) The 2011 appropriate use criteria for 
echocardiography were applied to 931 consecutive inpatients referred for transthoracic 
echocardiography in 5 community hospitals in Italy, who were compared with 259 patients who had 
been discharged without having been referred for an echocardiogram. The investigators determined 
that 14.7% of requested studies fell into the inappropriate category. However, among the patients 
discharged without an echocardiographic examination, 16.2% failed to have a study performed despite 
an appropriate indication, most commonly worsening signs or symptoms of heart failure. (10) 
The universe of clinical conditions in which an echocardiogram may be indicated is large, and the task of 
deciding at what point the study becomes a high value test is challenging even for physicians trained in 
cardiology. Determining in the clinic or at the bedside when an echocardiogram meets “high value” 
criteria may be even more difficult for non-cardiologists, such as internal medicine specialist or general 
practice physicians, who order 71% of echocardiograms. (36) What tools are available to assist clinicians 
in ordering appropriate imaging tests for a given patient, while refraining from ordering ones of low 
value? Clinical decision support systems, defined as “any electronic system designed to aid directly in 
clinical decision making, in which characteristics of individual patients are used to generate patient-
specific assessments or recommendations that are then presented to clinicians for consideration” are 
promising means by which to improve cardiac test ordering. (37) Four recent reviews found moderate 
strength evidence that decision support systems, integrated into computerized point of entry or 
electronic health record systems, can improve the appropriate ordering of clinical studies. Decision 
support systems varied in the effectiveness with which they improved the quality of care, as judged by 
health care process measures such as performing preventive services, diagnostic test ordering, and 
prescription of therapies. Data are sparse for effects on patient or economic outcomes. Few of the 
individual studies reviewed examined imaging. (38-41) 
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From the foregoing, a two-sided paradigm for achieving high value cardiac imaging emerges, as cardiac 
imaging must be “right sized” in two directions. The issue of inappropriate overutilization has been 
recognized, and tools to identify and address it are appearing. Those initiatives work towards the 
important goal of reducing the number of imaging studies where the ratio of positive outcomes to 
dollars spent is unfavorable. In a complimentary manner, research is needed into scenarios where 
inappropriate underutilization takes place. Circumstances where a favorable ratio of health care value 
achieved relative to cost indicates that a study is high value must not be missed.  A systematic approach 
for research into the latter would identify controlled trials of cardiac conditions where therapies which 
improve patient outcomes require imaging studies to detect candidates for treatment. Then, 
investigations would delineate methods which start with the patient at the point of care for his or her 
symptoms or condition, and alert care providers (some of whom may not be familiar with the nuances 
of appropriate cardiac testing) to order precisely the right test. An ideal system would provide real-time 
feedback so as to educate as well as inform the physician. Research would later be needed to discover 
whether beneficial changes take place in practice patterns, and more important in patient outcomes and 
societal efficacy.  
Progress in this direction is evident from a recent prospective study which evaluated an appropriate use 
criteria decision support tool for physicians ordering imaging studies for coronary artery disease. The 
studies included stress echocardiography, as well as myocardial perfusion scintigraphy and coronary CT 
angiography. In addition to examining the effects on test appropriateness, the investigators studied the 
effects of using the tool on intended changes in medical therapy. The tool was employed at the point of 
ordering, took on average two minutes of physician time to use, and the immediate feedback to the 
physician provided an educational component. Comparing the first two months and the last two months 
of the trial, ordering of rarely appropriate studies decreased from 22% to 6%, the percentage of 
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appropriate studies increased from 49% to 61%, and intended changes in medical therapy increased 
from 11% to 32%. (42) 
Multimodality, disease-specific appropriate use criteria for imaging are now beginning to appear with 
the publication of the 2013 document for cardiovascular imaging in heart failure. (43) This appropriate 
use document differs from prior publications not only because it is the first to encompass multiple 
imaging modalities. The authors identified five key clinical entry points or scenarios for heart failure-
directed imaging, “emphasizing that each indication represents the specific ‘point-of-order’ for an 
imaging study.” Each scenario reviews the rationale for imaging, delineates the choice of imaging 
modalities, references the heart failure guidelines, and categorizes the appropriateness of each 
modality. For the scenario “newly suspected or potential heart failure,” appropriate use 
recommendations drill down to selection of imaging based on symptoms and signs, for malignancy with 
cardiotoxic therapy, familial or genetic cardiomyopathy, known adult congenital heart disease, and 
acute myocardial infarction. 
Envisioning a system for promoting high value cardiac testing  
One can hypothesize the form which an ideal system to ensure high value cardiac imaging might take. 
The process would use a decision support tool at the point of care or ordering. It would begin with a set 
of signs and symptoms or a disease state. Logic built into the decision support algorithm could 
automatically pull patient-specific descriptors which are already present in the database, such as the 
physical examination, severity of symptoms, co-morbid conditions such as malignancy, prior relevant 
imaging or laboratory values such as creatinine, for its impact on choosing a dye study, among others. By 
referencing appropriate use criteria for multimodality imaging, the system could prompt the clinician to 
consider ordering an appropriate study for each specific case where indicated. It might be designed to 
look back to prior, similar testing  and, by matching elements in the report (such as mild, moderate or 
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severe regurgitation) and patient descriptors (such as symptom severity), inform the clinician whether a 
study meets guideline recommendations to repeat the study, or whether to refrain from doing so if 
these criteria are not met. 
A means to harmonize expert opinion from cardiology with guidelines for the same condition by experts 
in other disciplines might further improve test utilization. Conceptually, at least, clinicians might be most 
familiar with recommendations in their own specialty’s literature.  An example is syncope, a condition 
treated by emergency medicine specialists as well as cardiologists.  Syncope is ranked in the 
echocardiography appropriate use guidelines as appropriate for “clinical symptoms or signs consistent 
with a cardiac diagnosis known to cause lightheadedness/presyncope/syncope.” (44) Recommendations 
similar to these have been made in multidisciplinary guidelines for the investigation of syncope 
authored by experts in emergency medicine. (45, 46) Using decision rules found in the emergency 
medicine literature for patients presenting to emergency rooms with syncope may improve the 
diagnostic and therapeutic efficacy of echocardiography. Applying a syncope diagnostic protocol to 
patients presenting to a hospital in the United Kingdom increased the percentage of echocardiograms 
performed. Importantly, the authors noted that 75% of echocardiograms in the study group were 
performed for significant clinical findings such as aortic stenosis. Compared with historical controls, the 
number of examinations needed to make a diagnosis decreased significantly, implying that the 
percentage of low yield echocardiograms was reduced. (47)  
Efforts to reduce low value imaging represent an important start in ensuring appropriate use of 
resources. Short term benefits are relatively easy to quantitate, at least economically in terms of dollars 
saved. We must at the same time recognize and address the thornier problem of missed opportunities 
for high value imaging. As the United States moves to value-based purchasing, diagnoses will be bundled 
into payment groups, and pressure will mount to reduce costs. Physicians must improve the way they 
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order cardiac imaging, moving beyond cost to the concept of value. Inappropriate underutilization as 
well as overutilization must be reduced. In the latter case, failure to perform the right test at the right 
time can lead to an even more unfortunate circumstance for patients, described by hockey great Wayne 
Gretzky as “you miss 100% of the shots you never take.”  
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Figure Legends 
 
Figure 1. Dimensions of care framework for evaluating quality of cardiovascular imaging. 
From Douglas, P.; Chen, J.; Gillam, L.; Hendel, R.; Jollis, J.; Iskandrian, A.E.; Krumholz, H.M.; Massoudi, F.; 
Mohler, E. III; McNamara, R.L.; Patel, M.R.; Peterson, E.; Spertus, J. Achieving quality in cardiovascular 
imaging: proceedings from the American College of Cardiology-Duke University Medical Center Think 
Tank on Quality in Cardiovascular Imaging. J Am Coll Cardiol 2006;48:2141-2151. Reproduced with 
permission of Elsevier, Inc. 
 
 
